also specifically, during update GeoVax products clinical successfully we stage advancing GEO-CMXXSX, the in on therapy development critically you advanced progress more the next-generation while year, and status and cancer COVID-XX participating fourth to focused Today, a in II initiatives. our discuss against important call.
Last thank and vaccine. other and advanced neck and Gedeptin afternoon, our Phase the related developments, quarter, plans head currently for as corporate Good X we'll the
therapies Our goal innovative indications pursuing is business initial medical pathways. disease commercialization addressing via distribution support collaborations. registration to development, unmet expedited develop critically infectious cancer important partnerships vaccines, and anticipate and that worldwide and We needs,
comments, These and worldwide. patients we initial then difficulty Typically, update my be will represents of XX,XXX care. end-stage a your those closure are need. the swallow I/II and advanced and unmet addressed.
At neck they cancer care, in U.S. existing targeted trial among XXX,XXX Following medical exhausted population who for represent receiving patient patients. of the collative care and This and are standard Many have speaking. therapies of have to critical unable are will Mark food on an our Reynolds, Phase our provide Gedeptin questions and financials year-end, CFO, announced head the enrollment
patients Our of advancement an evidence and/or therapy has in life provide various earlier-stage goal this eliminating end-stage to in tumors clinical supporting to these by been disease. of provide quality and improved targeted shrinking
reflecting presented was stabilization in That July, initial trial As you reduction noted the conference data Montreal. and AHNS the feasible program.
Last may treated of size Orphan clinical under Gedeptin of shown recall, to the at Drugs trials be that tumors. this and/or presentation in administration were clinical funded by safe AACR was FDA results
of plans Gedeptin followed neck of with for by cancer. evaluation We discussing expect during to first results further and advanced XXXX, report the trial patients this in our head final half
cytoreductive or including burden, for considers Gedeptin to also with radiotherapy blockade in checkpoint earlier-stage a combination HNSCC with tumor strategy less role therapy neoadjuvant Our inhibition. similar
anticipate refer medical clinical of of replication-deficient critically virus vaccine populations a catalog. durable immune also it the compromised mechanism expedited to the the delivery well and an variants, needs potentially are need address approaches, immunocompromised represents tumor-agnostic, of of within path and also registration.
The multiple current across variants addressing and of others is vaccines, and Gedeptin antibody various which to functional vaccine the for in significant the friendly oncology response robust FDA of profile efficient immune conduct for system response meaning a trials partnering vaccine that and which immune more worldwide. present aims partnering and of vast targeting unmet mRNA a necessary clinical positions two hematologic enable technology, discussions continuous as safe array novel a various with GEO-CMXXSX providing whom appears with following to we to by more of to more public high-risk high-risk practical the addressing for the We booster as are without generated for against both of and in will the needs that advance to of related are use rights both XXXX opportunities mRNA receipt this important immune during general with current worldwide for arms us The [indiscernible]. this stimulating result will approved to COVID-XX solution patients. Phase the We we vaccines address robust action a CMXXSX, This vaccines tumors, as cellular use solid therapies COVID-XX to We hold of cancer patient cancers variety indications populations provide monoclonal and proven that data underway emerging with oncology antibody currently reconfiguration some discussions.
GEO-CMXXSX, all a our and II health vaccine durable individuals conferences participating than with vaccines.
Three a conducting next-generation the of in GeoVax through offered inadequate.
vaccine Moderna our to current unmet receipt vaccines.
Last prior vaccine. while for an we substantially a completed and reported who involves The from vaccine hope following immunological both month, trial had II the This September, variants cell include Pfizer previously mRNA variants The this against T as trial durable enrollment adults statistically the cellular the booster significant millions mRNA as trial /SARS-CoV-X events universal the Wuhan booster COVID-XX vaccines. waiting and Omicron the from specific value current X.X, among received demonstrating vaccine XX patients the of the SARS-CoV-X the other CMXXSX We trial, our antibodies multiple interim Phase ranging against addresses as well virulent responses mRNA indicating our robust or adverse responses. throughout needs this variants serious of SBB data vaccine. immunocompromised strain booster study we that positive responses.
Earlier more is the a as no original in Phase the increases immune in demonstrating authorized healthy Delta assessing in also highly neutralizing neutralizing II measured antibodies as robust, through a demonstrate for
patients. is in U.S. ability lupus, Final in blood there to respond trial over of it JAMA the placing the and updated, hospitalization mRNA in versus anticipated testing and to COVID-XX million to the with indicating these from we U.S., the of $XX critical the populations was of leading patients believe Worldwide, severe cancers, Many Additional the current such death.
Recently, reported of as and they individual, vaccine vaccine, clinical million. fourth are during the risk those with of $XXX of diseases XX needs been in adequately against patients.
Previously, the of include previous this estimated is $XX has immunocompromised X quarter major million. such or this of support significantly increased that the million the approved a variant number CMXXSX immunocompromised currently discussed a for need that February in patients they in potential as Such next-generation of support are monitoring population in are them renal XX-month their approximately transplant estimate of therapy-induced infection JN we've next-generation underway. development adults others various reflecting vaccines the COVID-XX these There is results limited disease XX variant individuals. disease, immunocompromised concern, autoimmune are immunosuppression. include year,
transplant in presented Congress During XXXX, World trial the international including cell data conferences, from initial D.C. Vaccine stem several Washington, was at
this the results demonstrated the in responses the These for confirming essential to immunocompromised In highlighted the particularly ability robust highly levels variant. individuals. strongly vaccine were strain past September findings earlier, immunogenicity induce peer-reviewed protection, article immune Omicron and [indiscernible] the T-cell journal what providing vaccines. in The illustrating published also vaccines addition, unique of antibody both protective XBBX.X Wuhan feature from mentioned way I through ancestral CMXXSX, all the
of trial been Initial Medical the however, Center patient trial we additional seek Hope pace accelerate the at City this into California. recently, More in to have occurred added as enrollments sites enrollment. of
[indiscernible] to actively from in Hope, the of North [indiscernible], X this X include Massachusetts [indiscernible] are sites Seattle, patients recruiting expansion Mass, Medical in Wake Carolina [indiscernible] addition The Center there of Cancer now trial. initially and Center patients In important enrolled critically Forest Medical in North [indiscernible] the in Carolina sites Center additional Carolina. of Center Medical Eastern Phase II City University
interest, While we and participating are currently internationally from both these in clinical patient and we've seen this domestically sites, enrollment study. focused considerable on optimizing
trial clinically of enrollment this with additional Pfizer-BioNTech mRNA to vaccine. underlying to comparing extreme trials generate expanding more Following due are August, mRNA of their them patients placing to these CMXXSX and the CLL the enroll approximately to unable of the at vaccination developing XX designed of in immunocompromised protective directly Typically, City patients last patient adequate malignancy continue initiation recently following recruit antibodies CLL patients trial levels investigator-initiated risk to among COVID-XX. evaluate severe locations.
The is Hope hematologic
of consequence, more began. remain X a pandemic the than years many homebound As these since patients
the CMXXSX developing path protection ongoing Results unserved desperately of believe immunocompromised these high-risk due these are can XXXX.
Relative for regulatory analysis half populations. exists to on the that from that offer an We first so trial an that an we need. interim are they anticipated individuals focus opportunity during expedited the buyers patients our such optimistic CMXXSX from
on Project announced April, CMXXSX Seeking with that improved enhanced We clinical to a COVID-XX of the White prime particularly of against like durability, to $X believe the I'd vaccines next-generation comment operation is vaccine protection variants insisted already NextGen. trials. [indiscernible]. Now in Last this breadth in vaccine. initiative billion desired and candidates House regarding COVID-XX novel example follow from
related to discussions Of program. formal we to be NextGen, $X funding for active Project $X with billion participation awarded. continue aside remains the over this in billion there the set Regarding still
we Beyond noting negotiations discussions in [indiscernible] and that participation, active time. this remain regarding we
anticipate opportunities targeted commercial we're leadership achieving for Finally, that Active in those to provide support area.
Overall, and this underway and areas initiatives within clinical worldwide we commercialization are CMXXSX, related partnering in and and basis addressing of a additional research efforts collaborations and us and distribution. markets. patient
patient that on exist the leadership focused current Gedeptin we're stage are of these Our potential currently achieving vaccine existing of clinical products, unserved therapeutic therapies. We and area. and by the focused populations vendor in addressing respective that populations believe CMXXSX, and vaccine needs product in
Also, our significant leadership shareholder a monopoly position GEO worldwide. the against [ stakeholder and MVA vaccine. and value area, a lives while important improve on of we're delivering differentiated to ], is smallpox disrupt us intended important supplier critically We're the to in an such that U.S.-based that course existing providing that global as build first products Mfox confident vaccine will
expanded our During for and this current Phase final our the we the year, Gedeptin, CMXXSX trial. report from plans with report results further and the And to programs. II trial Phase will from II results expect we progress
to plans further product report regulatory our to vaccine towards checkpoint Gedeptin therapy steps conjunction combination MVA to we as with anticipate expect immune against reporting to also in next advancing pox and smallpox, our and path inhibitors.
Relative evaluating regarding used related related that We registration. plans m
MVA our Geo-Vac summarize, Finally, needs targeted Gedeptin, to MVA-based needs, our care. market various MVA stage we enable to to of largely anticipate effectively updates further related important and of in to products, and clinical standard areas produce current vaccine products advanced CMXXSX response and distribute by manufacturing real-time medical process clinically represent worldwide.
To unserved
these these to registration represent the clinical potential perspective, More encouraging product believe with feasible the almost seeing we're a for expedited billion. opportunities consistent pleased estimated commercial $XX of potential products.
From annual are are path we our from an results U.S. We revenue trials.
basis to GeoVax reflection a address that's of that and we rather the this conjunction a relative need partners the worldwide Expanding shareholders critically in areas. for to the adds important to stakeholders. collaborators confidence and Now not with forecast, significance a to outlook have the sales but these of our
Now over review GeoVax's the I'd Mark Reynolds, recent to like and for financial presentation to Financial of Chief turn a status. our Mark? results Officer,
